Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.
J Clin Oncol. 2010 Oct 10;28(29):4521-30. doi: 10.1200/JCO.2010.29.7929. Epub 2010 Aug 9.
To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group.
In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized.
Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation.
New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.
代表国际骨髓瘤工作组，就异基因造血干细胞移植（Allo-SCT）作为多发性骨髓瘤（MM）的治疗选择达成共识声明。
在本综述中，总结了 MM 中前瞻性和回顾性 Allo-SCT 研究的结果。
尽管采用了减低强度的预处理（RIC）降低了与清髓性预处理相关的高治疗相关死亡率，但缺乏证据表明与自体造血干细胞移植相比，Allo-RIC 可改善生存。
需要新的策略来使 Allo-SCT 对 MM 患者更安全、更有效。在实现这一目标之前，RIC 在骨髓瘤中的应用仅应在临床试验的背景下推荐。
